SLC5A2 and heart failure: SGLT2 inhibitors such as dapagliflozin have been shown to reduce all-cause mortality and heart failure hospitalizations after transcatheter aortic valve replacement, while also being associated with improved cardiac remodeling, a lower risk of bioprosthetic valve failure, and a potential mitigation of kidney injury, especially in high-risk and diabetic patient populations [28].